Carrimycin is a macrolide antibiotic widely used in the pharmaceutical and clinical fields， with its primary composition consisting of three distinct derivatives of spiramycin...This work effectively advances spiramycin derivatives from compounds with observed phenotypic activity toward agents with an emerging mechanistic understanding， thereby paving the way for more targeted drug design and informed combination therapy strategies in oncology. Future studies will focus on delineating the detailed downstream consequences of APP engagement by h-SPM and exploring the therapeutic potential of other identified targets in preclinical models.

P2, N=150, Not yet recruiting, Icahn School of Medicine at Mount Sinai

GV1001 markedly mitigated these 5-FU-induced mitochondrial defects. Taken together, GV1001 mitigates CIM by most likely preserving mitochondrial integrity and function, supporting its potential as a strategy to prevent cancer chemotherapy-associated mucosal injury in patients.

P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | N=241 --> 366

P=N/A, N=917, Completed, Scripps Translational Science Institute | Enrolling by invitation --> Completed

P=N/A, N=350, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o

P=N/A, N=3347, Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center

P1, N=24, Recruiting, Traws Pharma, Inc.

GV1001 administered alone or in combination with cisplatin produced antitumor effects. Collectively, these findings demonstrate that GV1001 functions as a potent immunomodulatory anticancer peptide that downregulates CD47 expression and restores macrophage-mediated tumor clearance, highlighting its potential as a therapeutic strategy for OSCC.

P3, N=498, Recruiting, Simcere Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting

P2, N=165, Not yet recruiting, Traws Pharma, Inc.

P2/3, N=241, Recruiting, Airway Therapeutics, Inc.